Jie Ge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jie Ge has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Feng Su
Department of Nephrology, the First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - Jing Zhang
Department of Nephrology, the First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - JingYuan Ma
Department of Nephrology, the First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - Niroj Mali
Department of Nephrology, the First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - WenXing Fan
Department of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 7 April 2022
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 22 (1) , 1-12
Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials
Background: The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients. Methods: Eight databases (PubMed, Web of Science, the Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, and China Biology Medicine Database (CBM)) were searched for published articles to evaluate the clinical efficacy of liraglutide in subjects with T2DN. The Revman 5.3 and Stata 13 software were used for analyses and plotting. Results: A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened. We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide. Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF–α, IL-6). However, there was no significant difference in BUN and eGFR between the experimental group and the control group. Conclusions: Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function.
- 7 April 2022
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 22 (1) , 1-12
Open AccessEfficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials
Background: The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients. Methods: Eight databases (PubMed, Web of Science, the Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, and China Biology Medicine Database (CBM)) were searched for published articles to evaluate the clinical efficacy of liraglutide in subjects with T2DN. The Revman 5.3 and Stata 13 software were used for analyses and plotting. Results: A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened. We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide. Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF–α, IL-6). However, there was no significant difference in BUN and eGFR between the experimental group and the control group. Conclusions: Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function.